Gyre Therapeutics Inc. Common Stock (GYRE)
Stock · NASDAQ · Health Care
$6.08as of 10/16/2026
Price chart
Active signals
GYRE Signal Track Record
How signals performed across all stocks →What GYRE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -0.3% | 45% | September 24, 2026 |
| Bollinger Band Breakout | 28 | -5.8% | 32% | September 8, 2026 |
| Bollinger Band BreakdownActive now | 20 | +9.0% | 60% | May 7, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -14.3% | 20% | October 2, 2026 |
| Any 20-session window (baseline) | +0.3% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GYRE
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 625
- Website
- www.gyretx.com/
Fundamentals
- 1-day range
- $6.4$6.65
- Market cap
- $713.53M
- P/E (trailing)
- —
- P/E (forward)
- 106.67
- EPS (trailing)
- $-0.18
- Dividend yield
- —
- Beta
- 2.46
- Avg. volume
- 108.3K
- Dividend pay date
- January 12, 2023
How Gyre Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Gyre Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GYREGyre Therapeutics Inc. Common Stock$6.08▼ 5.00%Market cap $713.53MP/E —$5.44$9.42
- OCSOculis Holding AG Ordinary shares$7.29▼ 1.49%Market cap $717.85MP/E —$7.11$34.48
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
- RIGLRigel Pharmaceuticals Inc. Common Stock$45.97▼ 2.71%Market cap $732.62MP/E 2.76$24.95$52.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GYRE Gyre Therapeutics Inc. Common Stock | $713.53M | — | $6.08 | ▼ 5.00% | $5.44$9.42 |
| OCS Oculis Holding AG Ordinary shares | $717.85M | — | $7.29 | ▼ 1.49% | $7.11$34.48 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
| RIGL Rigel Pharmaceuticals Inc. Common Stock | $732.62M | 2.76 | $45.97 | ▼ 2.71% | $24.95$52.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Weston Claire · August 3, 2026 · Grant40.0K
- Kirkby Maxwell · August 3, 2026 · Grant40.0K
- Ye Weiguo · June 18, 2026 · Option Exercise3.0K @ $0.75
- Ye Weiguo · June 18, 2026 · Sale3.0K @ $6.35
- Ye Weiguo · June 11, 2026 · Option Exercise2.8K @ $0.75
- Ye Weiguo · June 11, 2026 · Sale2.8K @ $6.17
- Ye Weiguo · June 10, 2026 · Option Exercise5.0K @ $0.75
- Ye Weiguo · June 10, 2026 · Sale5.0K @ $6.24
- Ye Weiguo · June 10, 2026 · Sale6.4K @ $6.21
- Ye Weiguo · June 10, 2026 · Option Exercise6.4K @ $0.75
- Ye Weiguo · June 9, 2026 · Option Exercise3.0K @ $0.75
- Ye Weiguo · June 9, 2026 · Sale3.0K @ $6.15
- Ye Weiguo · June 9, 2026 · Option Exercise14.5K @ $0.75
- Ye Weiguo · June 9, 2026 · Sale14.5K @ $6.14
- Luo Ying · June 8, 2026 · Grant120.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.18M
- Total value held
- $22.16M
- Institutional holders
- 52
- Unknown984.2K
- Unknown758.6K
- Unknown431.4K
- Unknown216.3K
- Unknown170.8K
- Unknown165.2K
- Unknown133.8K
- Unknown73.1K
- Unknown43.1K
- Unknown25.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Gyre Therapeutics Schedules Investor Meetings for September
Gyre Therapeutics has announced participation in upcoming investor conferences scheduled for September. The company will engage with institutional investors and analysts through these scheduled meetings. Shares are currently trading near established support at $6.32, within a 52-week range of $5.44 to $9.42. Three analysts currently maintain an average price target of $18.67.
Gyre Therapeutics Schedules Investor Meetings for September. Gyre Therapeutics has announced participation in upcoming investor conferences scheduled for September. The company will engage with institutional investors and analysts through these scheduled meetings. Shares are currently trading near established support at $6.32, within a 52-week range of $5.44 to $9.42. Three analysts currently maintain an average price target of $18.67.